Active Biotech says first amended-protocol cohort clears safety review in HOVON 172 MF tasquinimod trial

• Active Biotech reported the first three-patient safety cohort completed a six-week evaluation in the HOVON 172 MF tasquinimod study.
• Results have been presented now as an interim safety update from patients enrolled under an amended dosing protocol.
• One serious adverse event met dose-limiting toxicity criteria, resolved with medical management, and the patient stayed on treatment.
• No additional dose-limiting toxicities were seen; all three patients remained on therapy, supporting continued development in myelofibrosis.
• Enrollment will expand to three more patients; the recommended Phase II dose regimen is expected once that safety check is completed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.